Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for C4 Therapeutics (CCCC) over the last 5 years, with Sep 2025 value amounting to $265.5 million.

  • C4 Therapeutics' Liabilities and Shareholders Equity fell 29.40% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 19.64%. This contributed to the annual value of $349.6 million for FY2024, which is 7.13% down from last year.
  • As of Q3 2025, C4 Therapeutics' Liabilities and Shareholders Equity stood at $265.5 million, which was down 10.47% from $296.5 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Liabilities and Shareholders Equity peaked at $528.4 million during Q2 2021, and registered a low of $265.5 million during Q3 2025.
  • Over the past 3 years, C4 Therapeutics' median Liabilities and Shareholders Equity value was $375.0 million (recorded in 2023), while the average stood at $351.6 million.
  • In the last 5 years, C4 Therapeutics' Liabilities and Shareholders Equity soared by 121.67% in 2021 and then declined by 29.40% in 2025.
  • Quarterly analysis of 5 years shows C4 Therapeutics' Liabilities and Shareholders Equity stood at $506.8 million in 2021, then fell by 14.98% to $430.8 million in 2022, then decreased by 12.62% to $376.5 million in 2023, then fell by 7.13% to $349.6 million in 2024, then declined by 29.40% to $265.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $265.5 million in Q3 2025, compared to $296.5 million in Q2 2025 and $319.5 million in Q1 2025.